Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes.

"Funding and Duality of Interest. Funding for this study was provided by Eli Lilly and Company. T.H. is shareholder of the private research institute Profil, which received research funds from Adocia, AstraZeneca, Biocon, Boehringer Ingelheim, Crinetics, Eli Lilly and Company, Gan & Lee Pharmaceuticals, Genova, Nestlé, Neuraly, Novo Nordisk, Sanofi, and Zealand Pharma; received speaker honoraria and travel grants from Eli Lilly and Company, Gan & Lee Pharmaceuticals, and Novo Nordisk; and is a member of advisory panels for Novo Nordisk. J.H.D. was on advisory boards for Adocia, Novo Nordisk, and Zealand. He is now at the European Medicines Agency, where he will not be involved in matters relating to tirzepatide. The clinical studies presented here preceded his secondment to the European Medicines Agency. S.U., J.L., E.J.P., M.K.T., K.J.M., C.A.K., J.D., A.H., Z.M., and T.C. are employees and shareholders of Eli Lilly and Company. M.K.T. also reports support for patents (planned, issued, or pending) from Eli Lilly and Company and participation in the steering committee for the Accelerating Medicines Partnership for Common Metabolic Diseases. A.H. also reports participation on a data safety monitoring board for multiple compounds. No other potential conflicts of interest relevant to this article were reported."

"Funding and Duality of Interest. Funding for this study was provided by Eli Lilly and Company. T.H. is shareholder of the private research institute Profil, which received research funds from Adocia, AstraZeneca, Biocon, Boehringer Ingelheim, Crinetics, Eli Lilly and Company, Gan & Lee Pharmaceuticals, Genova, Nestlé, Neuraly, Novo Nordisk, Sanofi, and Zealand Pharma; received speaker honoraria and travel grants from Eli Lilly and Company, Gan & Lee Pharmaceuticals, and Novo Nordisk; and is a member of advisory panels for Novo Nordisk. J.H.D. was on advisory boards for Adocia, Novo Nordisk, and Zealand. He is now at the European Medicines Agency, where he will not be involved in matters relating to tirzepatide. The clinical studies presented here preceded his secondment to the European Medicines Agency. S.U., J.L., E.J.P., M.K.T., K.J.M., C.A.K., J.D., A.H., Z.M., and T.C. are employees and shareholders of Eli Lilly and Company. M.K.T. also reports support for patents (planned, issued, or pending) from Eli Lilly and Company and participation in the steering committee for the Accelerating Medicines Partnership for Common Metabolic Diseases. A.H. also reports participation on a data safety monitoring board for multiple compounds. No other potential conflicts of interest relevant to this article were reported."